J C Garcia-Pagan

Summary

Affiliation: University of Barcelona
Country: Spain

Publications

  1. ncbi Influence of pharmacological agents on portal hemodynamics: basis for its use in the treatment of portal hypertension
    J C Garcia-Pagan
    Hepatic Hemodynamic Laboratory, Hospital Clinic, IDIBAPS, University of Barcelona, Spain
    Semin Liver Dis 19:427-38. 1999
  2. ncbi Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: a double-blind RCT
    Juan Carlos Garcia-Pagan
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malaties Digestives, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Hepatology 37:1260-6. 2003
  3. ncbi Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis
    J González-Abraldes
    Hepatic Hemodynamics Laboratory, Liver Unit, Institut de Malalties Digestives, Hospital Clinic, Institut de Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, Villaroel 170, 08036 Barcelona, Spain
    Gastroenterology 121:382-8. 2001
  4. ncbi Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: a multicentre randomised controlled trial
    J C Garcia-Pagan
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malalties Digestives i Metaboliques, Hospital Clinic, Institut de Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain
    Gut 58:1144-50. 2009
  5. ncbi Review article: the modern management of portal hypertension--primary and secondary prophylaxis of variceal bleeding in cirrhotic patients
    J C Garcia-Pagan
    Liver Unit, Hepatic Hemodynamic Laboratory, Hospital Clinic, IDIBAPS and Ciberehd, Barcelona, Spain
    Aliment Pharmacol Ther 28:178-86. 2008
  6. ncbi Primary prophylaxis of esophageal variceal bleeding in cirrhosis
    P Bellot
    Hepatic Hemodynamic Laboratory and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas Ciberehd, Liver Unit, IMD, Hospital Clinic, IDIBAPS, University of Barcelona, C Villarroel 170, 08036 Barcelona, Spain
    Gastroenterol Clin Biol 32:532-40. 2008
  7. ncbi Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension
    A Escorsell
    Hepatic Hemodynamic Laboratory, Liver Unit, University of Barcelona, Barcelona, Spain
    Hepatology 31:1061-7. 2000
  8. ncbi Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive beta-blockers
    J C Garcia-Pagan
    Hepatic Hemodynamic Laboratory, Liver Unit, IMD, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Gastroenterology 121:908-14. 2001
  9. ncbi Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats
    M D'AMICO
    Hepatic Hemodynamic Laboratory, Liver Unit and Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, University of Barcelona, Barcelona, Spain
    Am J Physiol Gastrointest Liver Physiol 302:G1191-8. 2012
  10. ncbi Superoxide dismutase gene transfer reduces portal pressure in CCl4 cirrhotic rats with portal hypertension
    B Laviña
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, Barcelona, Spain
    Gut 58:118-25. 2009

Collaborators

Detail Information

Publications14

  1. ncbi Influence of pharmacological agents on portal hemodynamics: basis for its use in the treatment of portal hypertension
    J C Garcia-Pagan
    Hepatic Hemodynamic Laboratory, Hospital Clinic, IDIBAPS, University of Barcelona, Spain
    Semin Liver Dis 19:427-38. 1999
    ..In addition, the way to monitor response and clinical efficacy of pharmacological agents is reviewed...
  2. ncbi Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: a double-blind RCT
    Juan Carlos Garcia-Pagan
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malaties Digestives, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Hepatology 37:1260-6. 2003
    ..However, the long-term use of this combination drug therapy is safe and may be an alternative in clinical conditions associated with a greater risk of bleeding...
  3. ncbi Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis
    J González-Abraldes
    Hepatic Hemodynamics Laboratory, Liver Unit, Institut de Malalties Digestives, Hospital Clinic, Institut de Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, Villaroel 170, 08036 Barcelona, Spain
    Gastroenterology 121:382-8. 2001
    ..propranolol (n = 15) in portal hypertensive patients with cirrhosis treated endoscopically after a variceal bleeding episode...
  4. ncbi Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: a multicentre randomised controlled trial
    J C Garcia-Pagan
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malalties Digestives i Metaboliques, Hospital Clinic, Institut de Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain
    Gut 58:1144-50. 2009
    ..The present study was aimed at evaluating this issue in a multicentre randomised controlled trial (RCT) and to correlate changes in hepatic venous pressure gradient (HVPG) during treatment with clinical outcomes..
  5. ncbi Review article: the modern management of portal hypertension--primary and secondary prophylaxis of variceal bleeding in cirrhotic patients
    J C Garcia-Pagan
    Liver Unit, Hepatic Hemodynamic Laboratory, Hospital Clinic, IDIBAPS and Ciberehd, Barcelona, Spain
    Aliment Pharmacol Ther 28:178-86. 2008
    ..Variceal bleeding is a life-threatening complication of liver cirrhosis with a high probability of recurrence. Treatment to prevent first bleeding or rebleeding is mandatory...
  6. ncbi Primary prophylaxis of esophageal variceal bleeding in cirrhosis
    P Bellot
    Hepatic Hemodynamic Laboratory and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas Ciberehd, Liver Unit, IMD, Hospital Clinic, IDIBAPS, University of Barcelona, C Villarroel 170, 08036 Barcelona, Spain
    Gastroenterol Clin Biol 32:532-40. 2008
    ..There is no evidence to support using beta-blockers with nitrates or spironolactone. In patients with contraindication or intolerance to beta-blockers, endoscopic band ligations are indicated...
  7. ncbi Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension
    A Escorsell
    Hepatic Hemodynamic Laboratory, Liver Unit, University of Barcelona, Barcelona, Spain
    Hepatology 31:1061-7. 2000
    ..As with HVPG response, a fall in variceal pressure of 20% or greater is associated with a very low risk of variceal bleeding. The combination of both parameters allows almost optimal prognostication...
  8. ncbi Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive beta-blockers
    J C Garcia-Pagan
    Hepatic Hemodynamic Laboratory, Liver Unit, IMD, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Gastroenterology 121:908-14. 2001
    ..The present study evaluates whether isosorbide-5-mononitrate (Is-MN) effectively prevents variceal bleeding in patients with contraindications or who could not tolerate beta-blockers...
  9. ncbi Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats
    M D'AMICO
    Hepatic Hemodynamic Laboratory, Liver Unit and Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, University of Barcelona, Barcelona, Spain
    Am J Physiol Gastrointest Liver Physiol 302:G1191-8. 2012
    ....
  10. ncbi Superoxide dismutase gene transfer reduces portal pressure in CCl4 cirrhotic rats with portal hypertension
    B Laviña
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, Barcelona, Spain
    Gut 58:118-25. 2009
    ..NO scavenging by superoxide (O(2)(-)) further contributes to a reduction of NO bioavailability in cirrhotic livers...
  11. ncbi Pharmacological treatment of portal hypertension
    J González-Abraldes
    Liver Unit, Hospital Clinic, Barcelona, Spain
    Curr Opin Investig Drugs 2:1407-13. 2001
    ..This review covers current developments in the treatment of portal hypertension...
  12. ncbi Prevention of recurrent variceal bleeding
    A Berzigotti
    Hepatic Hemodynamic Laboratory, Liver Unit, IMD, Hospital Clinic, IDIBAPS and Ciberehd, University of Barcelona, C Villarroel 170, 08036 Barcelona, Spain
    Dig Liver Dis 40:337-42. 2008
    ..Therefore, in this situation, transjugular intrahepatic porto-systemic shunt using polytetrafluoroethylene stents should be the treatment of choice...
  13. ncbi Assessment of portal hypertension in humans
    A Escorsell
    Hepatic Hemodynamic Laboratory, Institut de Malalties Digestives, Hospital Clinic, Institut D Investigació Biomedica August Pi Sunyer, Barcelona
    Clin Liver Dis 5:575-89. 2001
    ..These measurements must be repeated 3 to 4 weeks after the final dose of therapy has been reached to assess the risk of variceal bleeding or rebleeding...
  14. ncbi [Influence of blood coagulation disorders on hepatic vascular diseases and therapeutic possibilities]
    J C Garcia-Pagan
    Laboratorio de Hemodinámica Hepática, Servicio de Hepatologia, Institut Clinic de Malalties Digestives, Institut de Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, Barcelona
    Gastroenterol Hepatol 27:49-51. 2004